Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Work In Process (2023 - 2025)

Maxcyte (MXCT) has disclosed Work In Process for 3 consecutive years, with $400000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Work In Process rose 31.15% to $400000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $400000.0, a 31.15% increase, with the full-year FY2024 number at $270000.0, down 51.61% from a year prior.
  • Work In Process was $400000.0 for Q3 2025 at Maxcyte, up from $337000.0 in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $1.0 million in Q2 2023 to a low of $101000.0 in Q2 2024.
  • A 3-year average of $439927.3 and a median of $337000.0 in 2025 define the central range for Work In Process.
  • Peak YoY movement for Work In Process: plummeted 89.93% in 2024, then surged 233.66% in 2025.
  • Maxcyte's Work In Process stood at $558000.0 in 2023, then tumbled by 51.61% to $270000.0 in 2024, then skyrocketed by 48.15% to $400000.0 in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Work In Process are $400000.0 (Q3 2025), $337000.0 (Q2 2025), and $199000.0 (Q1 2025).